Imagine buying a gadget that everyone raves about, only to hear some users had serious issues. That’s Sarepta right now: their gene therapy for a rare disease was a hit, but some tragic side effects tanked the stock. The FDA paused sales, then changed its mind, and shares bounced back. Some experts think the stock could triple from here—but it’s a wild ride. If you’re into high-risk, high-reward plays, this is one to watch, but don’t bet the coffee fund! #Business #Market #investing